Related Experiment Videos
[Probucol treatment of hyperlipidemia]
1Second Department of Internal Medicine, School of Medicine, Kanazawa University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1994
Summary
Probucol effectively reduces total and LDL cholesterol in familial hypercholesterolemia patients. While it also lowers HDL cholesterol, this may enhance reverse cholesterol transport, potentially offering antiatherogenic benefits.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Context:
- Familial hypercholesterolemia (FH) is a genetic disorder causing high cholesterol levels.
- Probucol is a lipid-lowering drug with a unique mechanism of action.
- Understanding probucol's effects on lipid profiles and atherosclerosis is crucial.
Purpose:
- To evaluate the efficacy of probucol in lowering cholesterol in FH patients.
- To investigate the impact of probucol on HDL cholesterol and reverse cholesterol transport.
- To explore the potential antiatherogenic mechanisms of probucol.
Summary:
- Probucol significantly reduces total cholesterol (22%) and LDL cholesterol (17%) in heterozygous FH patients.
- The drug also lowers HDL cholesterol (40%), potentially by increasing cholesteryl ester transfer protein and decreasing HDL particle size.
- Probucol has demonstrated antiatherogenic effects in animal models and reduced xanthomas in humans.
Impact:
- Probucol's LDL-lowering and reverse cholesterol transport activation may contribute to its antiatherogenic properties.
- The drug's antioxidant effects further support its potential in managing atherosclerosis.
- Probucol offers a therapeutic option for FH patients, with potential benefits beyond simple lipid reduction.